Microbiology Quiz: Target Modification
20 questions · exam conditions
0:00
Target ModificationQuestion 1 of 20

The Ser531Leu mutation in the rpoB gene is a common cause of rifampin resistance in M. tuberculosis. From a structural standpoint, how can this single amino acid change abolish drug activity while preserving the essential function of RNA polymerase?

The mutation eliminates a key hydrogen bond with rifampin, and the bulky leucine side chain sterically hinders drug binding in the pocket.
The leucine residue is charged and electrostatically repels rifampin, while the original serine residue was neutral.
The mutation causes the RNA polymerase to use an alternative transcriptional start site that is not affected by rifampin.
The mutation greatly increases the catalytic rate of the polymerase, allowing transcription to outpace the inhibitory effect of rifampin.
← Back to quizzes

Microbiology Quiz

Microbiology Quiz: Target Modification

Practice Target Modification in Microbiology with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.

What this quiz covers

This quiz focuses on Target Modification, giving you a quick way to practice the rules, question types, and explanations that matter most for Microbiology.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

All questions

Question 1

The Ser531Leu mutation in the rpoB gene is a common cause of rifampin resistance in M. tuberculosis. From a structural standpoint, how can this single amino acid change abolish drug activity while preserving the essential function of RNA polymerase?

  1. The mutation eliminates a key hydrogen bond with rifampin, and the bulky leucine side chain sterically hinders drug binding in the pocket. (correct answer)
  2. The leucine residue is charged and electrostatically repels rifampin, while the original serine residue was neutral.
  3. The mutation causes the RNA polymerase to use an alternative transcriptional start site that is not affected by rifampin.
  4. The mutation greatly increases the catalytic rate of the polymerase, allowing transcription to outpace the inhibitory effect of rifampin.
Explanation: Rifampin binds to a pocket on the RNA polymerase beta-subunit that is near the RNA-DNA hybrid channel. The serine at position 531 is part of this pocket. Replacing the small, polar serine with the large, bulky, nonpolar leucine has two effects: 1) it can eliminate a hydrogen bond that helps anchor rifampin, and 2) the bulky side chain physically obstructs the space, preventing rifampin from binding effectively (steric hindrance). This local change is subtle enough that it does not disrupt the overall architecture and catalytic function of the enzyme, allowing transcription to proceed.
  • Distractor B is incorrect; leucine is nonpolar, not charged.
  • Distractor C is an incorrect mechanism; the polymerase function is preserved at its normal sites, just without drug inhibition.
  • Distractor D is incorrect; mutations conferring resistance typically either have no effect on catalytic rate or slightly decrease it (fitness cost), they do not increase it.

Question 2

Mutations in topoisomerase genes (gyrA, parC) can reduce fluoroquinolone binding. Some bacteria also acquire Qnr proteins, which bind to and protect DNA gyrase from fluoroquinolones. How does the level of resistance conferred by qnr genes typically compare to that conferred by target site mutations?

  1. Qnr proteins confer a very high level of resistance, often exceeding that of a single gyrA mutation.
  2. Qnr proteins confer resistance to older fluoroquinolones like nalidixic acid, while target mutations are required for resistance to newer agents like levofloxacin.
  3. The level of resistance is identical, as both mechanisms prevent the formation of the quinolone-gyrase-DNA complex with equal efficiency.
  4. Qnr proteins provide a low level of resistance that is often not clinically significant on its own but can facilitate the selection of target site mutations. (correct answer)
Explanation: When you encounter questions about fluoroquinolone resistance mechanisms, focus on understanding how different resistance strategies provide varying levels of protection and work together in clinical settings. Qnr proteins represent a unique resistance mechanism that physically binds to DNA gyrase and topoisomerase IV, creating a protective shield around these enzymes. However, this protection is incomplete—fluoroquinolones can still access their targets, just less efficiently. This results in modest increases in minimum inhibitory concentrations (MICs), typically 8-32 fold, which often remain below clinical breakpoints for resistance. The key insight is that Qnr proteins don't eliminate drug binding entirely; they reduce it. This low-level resistance becomes clinically significant because it creates a "stepping stone" effect. Bacteria with Qnr proteins can survive at intermediate drug concentrations that would kill fully susceptible bacteria, providing time and selective pressure for high-impact target site mutations in gyrA and parC to emerge. These chromosomal mutations directly alter the drug binding site, conferring much higher resistance levels. Option A is incorrect because Qnr-mediated resistance is characteristically low-level, not high. Option B incorrectly suggests drug-specific patterns—both mechanisms affect all fluoroquinolones, though to different degrees. Option C is wrong because the mechanisms work differently and provide unequal protection levels. Remember this principle: plasmid-mediated resistance mechanisms like Qnr often provide moderate protection that facilitates the evolution of high-level chromosomal resistance. This two-step process is common in antibiotic resistance development across many drug classes.

Question 3

A patient's blood culture grows Staphylococcus aureus that is resistant to oxacillin (MIC > 4 µg/mL) but susceptible to vancomycin. This resistance phenotype is stable and not reversed by beta-lactamase inhibitors. What is the most likely molecular basis for this finding?

  1. Acquisition of the mecA gene, which encodes an alternative penicillin-binding protein (PBP2a) with low affinity for beta-lactam antibiotics. (correct answer)
  2. Point mutations in the genes for native penicillin-binding proteins (e.g., PBP2x), leading to a gradual decrease in binding affinity for oxacillin.
  3. Modification of peptidoglycan precursors to terminate in D-Ala-D-Lactate, preventing transpeptidase cross-linking in the presence of oxacillin.
  4. Hyperproduction of a type A beta-lactamase that efficiently hydrolyzes oxacillin despite its classification as a penicillinase-stable antibiotic.
Explanation: High-level, stable oxacillin resistance in S. aureus defines it as MRSA (methicillin-resistant S. aureus) and is mediated by the acquisition of the mecA gene. This gene encodes PBP2a, a transpeptidase that is not effectively inhibited by most beta-lactam antibiotics, allowing cell wall synthesis to continue in their presence.
  • Distractor B describes the mechanism of penicillin resistance in Streptococcus pneumoniae, which involves mosaic genes and altered native PBPs, not the acquisition of a novel PBP typical of MRSA.
  • Distractor C describes the mechanism of vancomycin resistance in enterococci (VRE), which involves altering the peptidoglycan target itself, not the PBP enzyme.
  • Distractor D is incorrect because while beta-lactamase hyperproduction can cause borderline oxacillin resistance, it is not the mechanism for high-level resistance, and oxacillin is designed to be stable against typical staphylococcal beta-lactamases.

Question 4

A multidrug-resistant isolate of Acinetobacter baumannii contains the sul1 gene located on a class 1 integron. This gene confers high-level resistance to sulfamethoxazole. How does the protein product of sul1 mediate this resistance?

  1. It is a drug-insensitive variant of dihydropteroate synthase that continues folate synthesis in the presence of sulfonamides. (correct answer)
  2. It is a drug-insensitive variant of dihydrofolate reductase that bypasses the inhibitory effects of trimethoprim.
  3. It is a drug-modifying enzyme that acetylates the sulfonamide group, rendering the antibiotic inactive.
  4. It functions as a transcription factor that upregulates the production of para-aminobenzoic acid (PABA), outcompeting the drug.
Explanation: Sulfonamides are structural analogs of PABA and act by competitively inhibiting dihydropteroate synthase (DHPS), a key enzyme in the bacterial folate synthesis pathway. The sul1 gene (and related sul genes) encodes a variant form of DHPS that has a very low affinity for sulfonamides but can still efficiently use PABA to synthesize folate precursors. This allows the pathway to function even in the presence of the drug.
  • Distractor B describes the mechanism of trimethoprim resistance, which involves the next enzyme in the pathway, dihydrofolate reductase.
  • Distractor C describes a plausible but incorrect mechanism of enzymatic inactivation.
  • Distractor D describes target overproduction/bypass, which is a different mechanism from acquiring a drug-insensitive target enzyme.

Question 5

Tetracycline resistance in many anaerobic and Gram-positive bacteria is mediated by ribosomal protection proteins (RPPs), such as Tet(M) and Tet(O). Which statement provides the most accurate description of the mechanism of action of these proteins?

  1. RPPs bind to the A-site of the 30S ribosomal subunit and enzymatically cleave the tetracycline molecule.
  2. RPPs are transcriptional repressors that prevent the expression of ribosomal proteins when tetracycline is present.
  3. RPPs are structural homologs of elongation factor G (EF-G) that bind to the ribosome and dislodge the bound tetracycline molecule in a GTP-dependent manner. (correct answer)
  4. RPPs methylate the 16S rRNA at the primary tetracycline binding site, sterically preventing the antibiotic from binding.
Explanation: Ribosomal protection proteins are a unique form of resistance. They are GTPases that have structural similarity to the elongation factors EF-G and EF-Tu. When tetracycline is bound to its primary site on the ribosome (blocking the A-site), an RPP like Tet(M) can still bind to the ribosome. Upon GTP hydrolysis, the RPP causes a conformational change in the ribosome that releases the tetracycline molecule, thus allowing translation to resume.
  • Distractor A is incorrect; RPPs do not enzymatically modify the drug.
  • Distractor B is incorrect; RPPs act post-translationally at the ribosome level.
  • Distractor D describes a different mechanism of resistance (enzymatic target modification), which is not how RPPs function.

Question 6

A Staphylococcus aureus isolate shows in vitro resistance to erythromycin but susceptibility to clindamycin. However, when the disks are placed near each other on an agar plate, a D-shaped zone of inhibition forms around the clindamycin disk. This phenotype is most consistent with which molecular mechanism?

  1. Constitutive expression of an erm gene product that methylates 23S rRNA, altering the binding site for both drugs.
  2. Inducible expression of an erm gene product, where erythromycin acts as an inducer for the methylation of the 23S rRNA target. (correct answer)
  3. Presence of an msrA gene encoding an efflux pump that is specific for 14- and 15-membered macrolides like erythromycin.
  4. A chromosomal mutation in the gene for ribosomal protein L4 that affects erythromycin binding but not clindamycin binding.
Explanation: The D-test phenotype is a hallmark of inducible MLSb (Macrolide-Lincosamide-Streptogramin B) resistance. The isolate possesses an erm gene, but its expression is induced only in the presence of an inducer, typically a 14- or 15-membered macrolide like erythromycin. Where erythromycin diffuses, it induces erm expression, leading to methylation of the 23S rRNA and subsequent resistance to clindamycin, creating the flattened, D-shaped zone.
  • Distractor A is incorrect because constitutive expression would result in the isolate being resistant to both drugs in standard testing.
  • Distractor C is incorrect because an efflux pump (msrA) would not cause inducible resistance to clindamycin; the organism would remain susceptible to clindamycin.
  • Distractor D describes a possible mechanism for erythromycin-only resistance but does not explain the inducible nature of the clindamycin resistance.

Question 7

A patient being treated for pulmonary tuberculosis shows clinical failure after two months of therapy. Genotypic drug susceptibility testing on the Mycobacterium tuberculosis isolate reveals a Ser531Leu mutation in the rpoB gene. What is the direct functional consequence of this specific mutation?

  1. It alters the catalytic site of DNA gyrase, preventing inhibition of DNA supercoiling by fluoroquinolones.
  2. It modifies the beta-subunit of the DNA-dependent RNA polymerase, reducing the binding affinity of rifampin. (correct answer)
  3. It changes the structure of arabinosyltransferase, preventing the inhibitory action of ethambutol on cell wall synthesis.
  4. It causes overexpression of the InhA protein, leading to resistance against the prodrug isoniazid.
Explanation: The rpoB gene encodes the beta-subunit of bacterial RNA polymerase. This subunit contains the binding pocket for rifampin. Mutations within a specific 81-bp region of rpoB, such as the common Ser531Leu substitution, alter this pocket, preventing rifampin from binding and inhibiting transcription. This is the primary mechanism of rifampin resistance.
  • Distractor A describes fluoroquinolone resistance, which involves mutations in gyrA/B.
  • Distractor C describes ethambutol resistance, which involves mutations in the emb genes.
  • Distractor D describes one mechanism of isoniazid resistance, which involves the mycolic acid synthesis pathway.

Question 8

A clinical isolate of Pseudomonas aeruginosa develops high-level resistance to ciprofloxacin after prolonged therapy. Initial isolates showed only low-level resistance. What sequence of genetic events most likely explains the evolution from low-level to high-level resistance?

  1. A single point mutation in the gyrA gene, leading to a conformational change in DNA gyrase.
  2. Initial acquisition of a plasmid-mediated qnr gene followed by upregulation of the MexCD-OprJ efflux pump.
  3. An initial mutation in the primary target gene, gyrA, followed by a secondary mutation in the parC gene. (correct answer)
  4. An initial mutation in the secondary target gene, parC, followed by a secondary mutation in the gyrA gene.
Explanation: In many Gram-negative bacteria like P. aeruginosa and E. coli, high-level fluoroquinolone resistance typically develops in a stepwise manner through target modification. The primary target is DNA gyrase (encoded by gyrA and gyrB). An initial mutation in gyrA confers low-level resistance. Subsequent mutations in the secondary target, topoisomerase IV (encoded by parC and parE), are then required to achieve high-level resistance.
  • Distractor A is incorrect because a single mutation in gyrA typically results in only low- to moderate-level resistance.
  • Distractor B describes two valid resistance mechanisms (target protection and efflux), but high-level resistance almost always involves mutations in the primary target enzymes.
  • Distractor D has the order reversed. For P. aeruginosa, DNA gyrase is the primary target, so mutations in gyrA usually precede those in parC.

Question 9

A researcher performs a binding assay using radiolabeled gentamicin and purified 70S ribosomes from a susceptible (S) and a resistant (R) strain of Enterococcus faecalis. The resistant strain is known to lack aminoglycoside-modifying enzymes. The results show that a 50-fold higher concentration of unlabeled gentamicin is needed to displace the radiolabel from the R ribosomes compared to the S ribosomes. Which is the most likely molecular basis for this resistance?

  1. Methylation of a specific nucleotide in the 16S rRNA component of the 30S ribosomal subunit. (correct answer)
  2. Upregulation of an efflux pump in the resistant strain that was co-purified with the ribosomes.
  3. A mutation in the rpsL gene altering the S12 ribosomal protein structure in the 30S subunit.
  4. A conformational change in the 50S subunit that allosterically affects the A-site in the 30S subunit.
Explanation: The experimental data directly demonstrate reduced binding of the drug to its target, the ribosome. High-level, transferable resistance to gentamicin and other aminoglycosides is often mediated by 16S rRNA methyltransferases (e.g., ArmA, RmtB). These enzymes methylate a specific site (e.g., G1405) in the A-site of the 16S rRNA, which is the primary binding site for many aminoglycosides, thereby preventing the drug from binding.
  • Distractor B is incorrect because an in vitro assay with purified ribosomes would not include functional, energy-dependent efflux pumps.
  • Distractor C, a mutation in rpsL, is a valid target modification mechanism for aminoglycoside resistance but typically confers resistance to streptomycin, not high-level resistance to gentamicin.
  • Distractor D is less specific and, while plausible, methylation of the direct binding site is a well-established mechanism that perfectly explains the data for high-level gentamicin resistance.

Question 10

During prolonged daptomycin therapy for a Staphylococcus aureus bacteremia, the isolate develops resistance. Genetic analysis reveals a gain-of-function mutation in mprF, a gene encoding a lysyl-phosphatidylglycerol synthetase. How does this mutation lead to daptomycin resistance?

  1. It increases the positive net charge of the outer leaflet of the cytoplasmic membrane, causing electrostatic repulsion of the drug. (correct answer)
  2. It alters the structure of the D-Ala-D-Ala terminus of lipid II, which is the primary binding target for daptomycin.
  3. It incorporates lysine into the peptidoglycan interbridge, which sterically hinders the insertion of daptomycin into the membrane.
  4. It activates an efflux pump system that specifically recognizes and exports the daptomycin-calcium complex from the cell.
Explanation: Daptomycin is a cationic lipopeptide that, complexed with calcium, targets the bacterial cell membrane. The MprF protein is a bifunctional enzyme that synthesizes lysyl-phosphatidylglycerol (L-PG) and flips it to the outer leaflet of the membrane. The addition of the positively charged lysine to the anionic phosphatidylglycerol reduces the net negative charge of the membrane, making it more positive. This increased positive charge repels the positively charged daptomycin-calcium complex, preventing it from effectively binding to and disrupting the membrane.
  • Distractor B is incorrect; daptomycin targets the cell membrane, not the peptidoglycan precursor like vancomycin.
  • Distractor C is incorrect; mprF modifies membrane lipids, not the peptidoglycan structure.
  • Distractor D describes a different resistance mechanism; mprF is involved in modifying the target environment (the membrane).

Question 11

Both penicillin-resistant Streptococcus pneumoniae (PRSP) and methicillin-resistant Staphylococcus aureus (MRSA) show resistance to beta-lactams through PBP modification. Which statement accurately contrasts the molecular events leading to high-level resistance in these two pathogens?

  1. MRSA acquires a novel PBP gene (mecA) from an external source, whereas PRSP develops resistance through sequential point mutations in its native PBP genes.
  2. MRSA acquires a novel PBP gene (mecA), whereas PRSP creates low-affinity PBP variants by incorporating foreign DNA into its native PBP genes, forming mosaic structures. (correct answer)
  3. Both pathogens acquire the mecA gene, but PRSP expresses it at a lower level than MRSA, resulting in a different resistance profile.
  4. PRSP modifies its cell wall precursors to prevent PBP binding, while MRSA modifies the PBP enzyme itself.
Explanation: This question tests a nuanced distinction. MRSA resistance is classic target bypass/replacement via acquisition of the mecA gene, which encodes a new, low-affinity PBP2a. In contrast, high-level penicillin resistance in S. pneumoniae arises from a more complex process where its native PBP genes (pbp1a, pbp2x, pbp2b) undergo recombination with DNA from closely related commensal streptococci. This creates 'mosaic' PBP genes that encode enzymes with reduced affinity for penicillins.
  • Distractor A is partially correct but less precise; the process in PRSP is not just simple point mutations but homologous recombination leading to mosaic genes.
  • Distractor C is incorrect; PRSP does not acquire or use the mecA gene.
  • Distractor D is incorrect; both pathogens modify the PBP enzyme, not the cell wall precursor, for beta-lactam resistance.

Question 12

Rifampin resistance in Mycobacterium tuberculosis is primarily due to chromosomal mutations in rpoB, while tetracycline resistance in Bacteroides is often due to the acquisition of the tet(Q) gene on a mobile element. What is a primary epidemiological difference resulting from these distinct genetic mechanisms?

  1. Rifampin resistance is more likely to be associated with a significant fitness cost than tetracycline resistance.
  2. Tetracycline resistance can be transferred horizontally between bacterial species, whereas rifampin resistance is mainly passed vertically to progeny. (correct answer)
  3. Rifampin resistance is inducible and only expressed in the presence of the drug, whereas tetracycline resistance is constitutive.
  4. Chromosomal mutations conferring rifampin resistance are highly unstable and revert quickly, unlike mobile element-mediated resistance.
Explanation: The genetic location of a resistance determinant has major epidemiological consequences. A chromosomal mutation, like those in rpoB, is passed down to daughter cells during division (vertical gene transfer). A gene on a mobile genetic element, like a conjugative transposon carrying tet(Q), can be transferred between different bacteria, even across species barriers (horizontal gene transfer). This allows for much more rapid and widespread dissemination of the resistance trait in a population.
  • Distractor A may be true in some cases, but it's not the most fundamental epidemiological difference. The mode of transmission is key.
  • Distractor C is incorrect; both mechanisms typically result in constitutive resistance once present.
  • Distractor D is incorrect; chromosomal mutations are generally very stable.

Question 13

A strain of E. coli exhibits resistance to the combination of trimethoprim-sulfamethoxazole. Genetic analysis reveals the presence of a plasmid carrying both sul2 and dfrA5 genes. Which statement best describes the combined mechanism of resistance in this organism?

  1. The organism produces altered forms of both dihydropteroate synthase and dihydrofolate reductase that are insensitive to the respective drugs. (correct answer)
  2. The organism overproduces the PABA precursor and bypasses the need for dihydrofolate reductase, rendering both drugs ineffective.
  3. The plasmid encodes a wide-spectrum efflux pump that actively removes both trimethoprim and sulfamethoxazole from the cytoplasm.
  4. The organism modifies both drugs enzymatically, with one enzyme acetylating trimethoprim and another phosphorylating sulfamethoxazole.
Explanation: This question requires recognizing the functions of two different acquired resistance genes that target the same metabolic pathway. The sul genes (like sul2) encode a drug-resistant variant of dihydropteroate synthase, conferring resistance to sulfamethoxazole. The dfr genes (like dfrA5) encode a drug-resistant variant of dihydrofolate reductase, conferring resistance to trimethoprim. By acquiring both genes, the bacterium establishes a complete folate synthesis pathway that is resistant to inhibition at two critical steps.
  • Distractor B is incorrect; the organism does not bypass the pathway but rather makes the pathway's enzymes resistant.
  • Distractor C describes a different mechanism (efflux). While some pumps can export these drugs, the specified genes mediate target modification.
  • Distractor D describes drug inactivation, which is not the function of sul or dfr gene products.

Question 14

Tetracycline resistance in many anaerobic and Gram-positive bacteria is mediated by ribosomal protection proteins (RPPs), such as Tet(M) and Tet(O). Which statement provides the most accurate description of the mechanism of action of these proteins?

  1. RPPs bind to the A-site of the 30S ribosomal subunit and enzymatically cleave the tetracycline molecule.
  2. RPPs are transcriptional repressors that prevent the expression of ribosomal proteins when tetracycline is present.
  3. RPPs are structural homologs of elongation factor G (EF-G) that bind to the ribosome and dislodge the bound tetracycline molecule in a GTP-dependent manner. (correct answer)
  4. RPPs methylate the 16S rRNA at the primary tetracycline binding site, sterically preventing the antibiotic from binding.
Explanation: Ribosomal protection proteins are a unique form of resistance. They are GTPases that have structural similarity to the elongation factors EF-G and EF-Tu. When tetracycline is bound to its primary site on the ribosome (blocking the A-site), an RPP like Tet(M) can still bind to the ribosome. Upon GTP hydrolysis, the RPP causes a conformational change in the ribosome that releases the tetracycline molecule, thus allowing translation to resume.
  • Distractor A is incorrect; RPPs do not enzymatically modify the drug.
  • Distractor B is incorrect; RPPs act post-translationally at the ribosome level.
  • Distractor D describes a different mechanism of resistance (enzymatic target modification), which is not how RPPs function.

Question 15

A trimethoprim-resistant E. coli strain with a mutation in the chromosomal folA gene (Strain A) is co-cultured with a resistant strain carrying a plasmid-borne dfrA1 gene (Strain B). In a drug-free medium, Strain B consistently outcompetes Strain A. What is the most likely reason for the lower relative fitness of Strain A?

  1. The folA mutation reverts at a high frequency, making the population susceptible again.
  2. Maintaining a chromosomal mutation is more energetically costly for the cell than maintaining a multi-copy plasmid.
  3. The plasmid in Strain B also carries genes for enhanced nutrient uptake, providing a competitive advantage.
  4. The altered chromosomal dihydrofolate reductase in Strain A has reduced catalytic efficiency for its natural substrate, slowing metabolic processes. (correct answer)
Explanation: When analyzing bacterial fitness in the context of antibiotic resistance, you need to consider how resistance mechanisms affect normal cellular functions. Resistance often comes with a fitness cost because the same proteins that confer resistance must also perform their natural cellular roles. The folA gene encodes dihydrofolate reductase (DHFR), an essential enzyme in the folate pathway that's crucial for DNA synthesis and one-carbon metabolism. When this enzyme is mutated to resist trimethoprim binding, the structural changes that prevent drug binding often simultaneously reduce the enzyme's ability to process its natural substrate, dihydrofolate. This creates a metabolic bottleneck that slows growth even in the absence of the drug, explaining why Strain A has lower fitness than Strain B. Option A is incorrect because reversion mutations are typically rare events and wouldn't consistently explain the fitness difference observed. Option B misunderstands the energetics involved—plasmids actually require more energy to maintain and replicate than chromosomal mutations, making this backwards. Option C introduces an unsupported assumption about additional plasmid genes that isn't mentioned in the question stem. The key insight here is that resistance mutations in essential genes create a trade-off: the protein becomes less susceptible to the drug but also less efficient at its normal function. This is why option D correctly identifies the reduced catalytic efficiency as the fitness cost. Study tip: Remember that antibiotic resistance often comes with fitness costs, especially when resistance involves mutations to essential enzymes. The same structural changes that block drug binding can impair normal enzyme function.

Question 16

A microbiology laboratory reports a Staphylococcus epidermidis isolate from a prosthetic joint infection as clindamycin-susceptible (MIC = 0.25 µg/mL) and erythromycin-resistant (MIC = 16 µg/mL). An infectious diseases pharmacist recommends against using clindamycin for long-term therapy. Which molecular finding would provide the strongest justification for this recommendation?

  1. The presence of an inducible ermC gene. (correct answer)
  2. The presence of an msr(A) gene encoding an efflux pump.
  3. The presence of an mph(C) gene encoding a macrolide phosphotransferase.
  4. A point mutation in the gene for the 23S rRNA.
Explanation: This clinical scenario describes the risk of treatment failure due to inducible MLSb resistance. The presence of an inducible erm gene (like ermC) means the bacterium appears susceptible to clindamycin in initial tests. However, during therapy, exposure to clindamycin (or selection of constitutively resistant mutants) can induce or select for expression of the methylase. This enzyme then modifies the ribosomal target, rendering the organism resistant to clindamycin and leading to clinical failure. The other mechanisms do not pose this specific risk.
  • Distractor B: The Msr(A) efflux pump confers resistance to macrolides but not clindamycin. Clindamycin therapy would be effective.
  • Distractor C: A macrolide phosphotransferase inactivates erythromycin but not clindamycin. Clindamycin therapy would be effective.
  • Distractor D: A point mutation would likely confer constitutive resistance, which would have been detected in the initial susceptibility test (i.e., the MIC would have been high).

Question 17

A patient's blood culture grows Staphylococcus aureus that is resistant to oxacillin (MIC > 4 µg/mL) but susceptible to vancomycin. This resistance phenotype is stable and not reversed by beta-lactamase inhibitors. What is the most likely molecular basis for this finding?

  1. Acquisition of the mecA gene, which encodes an alternative penicillin-binding protein (PBP2a) with low affinity for beta-lactam antibiotics. (correct answer)
  2. Point mutations in the genes for native penicillin-binding proteins (e.g., PBP2x), leading to a gradual decrease in binding affinity for oxacillin.
  3. Modification of peptidoglycan precursors to terminate in D-Ala-D-Lactate, preventing transpeptidase cross-linking in the presence of oxacillin.
  4. Hyperproduction of a type A beta-lactamase that efficiently hydrolyzes oxacillin despite its classification as a penicillinase-stable antibiotic.
Explanation: High-level, stable oxacillin resistance in S. aureus defines it as MRSA (methicillin-resistant S. aureus) and is mediated by the acquisition of the mecA gene. This gene encodes PBP2a, a transpeptidase that is not effectively inhibited by most beta-lactam antibiotics, allowing cell wall synthesis to continue in their presence.
  • Distractor B describes the mechanism of penicillin resistance in Streptococcus pneumoniae, which involves mosaic genes and altered native PBPs, not the acquisition of a novel PBP typical of MRSA.
  • Distractor C describes the mechanism of vancomycin resistance in enterococci (VRE), which involves altering the peptidoglycan target itself, not the PBP enzyme.
  • Distractor D is incorrect because while beta-lactamase hyperproduction can cause borderline oxacillin resistance, it is not the mechanism for high-level resistance, and oxacillin is designed to be stable against typical staphylococcal beta-lactamases.

Question 18

A clinical isolate of Pseudomonas aeruginosa develops high-level resistance to ciprofloxacin after prolonged therapy. Initial isolates showed only low-level resistance. What sequence of genetic events most likely explains the evolution from low-level to high-level resistance?

  1. A single point mutation in the gyrA gene, leading to a conformational change in DNA gyrase.
  2. Initial acquisition of a plasmid-mediated qnr gene followed by upregulation of the MexCD-OprJ efflux pump.
  3. An initial mutation in the primary target gene, gyrA, followed by a secondary mutation in the parC gene. (correct answer)
  4. An initial mutation in the secondary target gene, parC, followed by a secondary mutation in the gyrA gene.
Explanation: In many Gram-negative bacteria like P. aeruginosa and E. coli, high-level fluoroquinolone resistance typically develops in a stepwise manner through target modification. The primary target is DNA gyrase (encoded by gyrA and gyrB). An initial mutation in gyrA confers low-level resistance. Subsequent mutations in the secondary target, topoisomerase IV (encoded by parC and parE), are then required to achieve high-level resistance.
  • Distractor A is incorrect because a single mutation in gyrA typically results in only low- to moderate-level resistance.
  • Distractor B describes two valid resistance mechanisms (target protection and efflux), but high-level resistance almost always involves mutations in the primary target enzymes.
  • Distractor D has the order reversed. For P. aeruginosa, DNA gyrase is the primary target, so mutations in gyrA usually precede those in parC.

Question 19

Both penicillin-resistant Streptococcus pneumoniae (PRSP) and methicillin-resistant Staphylococcus aureus (MRSA) show resistance to beta-lactams through PBP modification. Which statement accurately contrasts the molecular events leading to high-level resistance in these two pathogens?

  1. MRSA acquires a novel PBP gene (mecA) from an external source, whereas PRSP develops resistance through sequential point mutations in its native PBP genes.
  2. MRSA acquires a novel PBP gene (mecA), whereas PRSP creates low-affinity PBP variants by incorporating foreign DNA into its native PBP genes, forming mosaic structures. (correct answer)
  3. Both pathogens acquire the mecA gene, but PRSP expresses it at a lower level than MRSA, resulting in a different resistance profile.
  4. PRSP modifies its cell wall precursors to prevent PBP binding, while MRSA modifies the PBP enzyme itself.
Explanation: This question tests a nuanced distinction. MRSA resistance is classic target bypass/replacement via acquisition of the mecA gene, which encodes a new, low-affinity PBP2a. In contrast, high-level penicillin resistance in S. pneumoniae arises from a more complex process where its native PBP genes (pbp1a, pbp2x, pbp2b) undergo recombination with DNA from closely related commensal streptococci. This creates 'mosaic' PBP genes that encode enzymes with reduced affinity for penicillins.
  • Distractor A is partially correct but less precise; the process in PRSP is not just simple point mutations but homologous recombination leading to mosaic genes.
  • Distractor C is incorrect; PRSP does not acquire or use the mecA gene.
  • Distractor D is incorrect; both pathogens modify the PBP enzyme, not the cell wall precursor, for beta-lactam resistance.

Question 20

Rifampin resistance in Mycobacterium tuberculosis is primarily due to chromosomal mutations in rpoB, while tetracycline resistance in Bacteroides is often due to the acquisition of the tet(Q) gene on a mobile element. What is a primary epidemiological difference resulting from these distinct genetic mechanisms?

  1. Rifampin resistance is more likely to be associated with a significant fitness cost than tetracycline resistance.
  2. Tetracycline resistance can be transferred horizontally between bacterial species, whereas rifampin resistance is mainly passed vertically to progeny. (correct answer)
  3. Rifampin resistance is inducible and only expressed in the presence of the drug, whereas tetracycline resistance is constitutive.
  4. Chromosomal mutations conferring rifampin resistance are highly unstable and revert quickly, unlike mobile element-mediated resistance.
Explanation: The genetic location of a resistance determinant has major epidemiological consequences. A chromosomal mutation, like those in rpoB, is passed down to daughter cells during division (vertical gene transfer). A gene on a mobile genetic element, like a conjugative transposon carrying tet(Q), can be transferred between different bacteria, even across species barriers (horizontal gene transfer). This allows for much more rapid and widespread dissemination of the resistance trait in a population.
  • Distractor A may be true in some cases, but it's not the most fundamental epidemiological difference. The mode of transmission is key.
  • Distractor C is incorrect; both mechanisms typically result in constitutive resistance once present.
  • Distractor D is incorrect; chromosomal mutations are generally very stable.